Glaukos Corporation (NYSE:GKOS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.
(a)The annual meeting of stockholders (the Annual Meeting) of
Glaukos Corporation (the Company) was held on May31, 2017.
(b)At the Annual Meeting, the Company’s stockholders (i)elected
the three nominees identified in the table below to the Board of
Directors of the Company to serve as ClassII directors until the
Company’s 2020 annual meeting of stockholders and until their
respective successors are duly elected and qualified and
(ii)ratified the appointment of Ernst Young LLP as the Company’s
independent registered public accounting firm for the year ending
December31, 2017.
Set forth below are the final voting tallies for the Annual
Meeting:
Election of Directors
|
For |
Withheld |
Broker NonVotes |
|
|
William J. Link, PhD. |
15,604,791 |
10,407,538 |
4,816,515 |
|
Jonathan T. Silverstein |
16,977,137 |
9,035,192 |
4,816,515 |
|
Aimee S. Weisner |
17,554,554 |
8,457,775 |
4,816,515 |
Auditor Ratification
|
For |
Against |
Abstain |
|
30,756,908 |
51,241 |
20,695 |
About Glaukos Corporation (NYSE:GKOS)
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients. Glaukos Corporation (NYSE:GKOS) Recent Trading Information
Glaukos Corporation (NYSE:GKOS) closed its last trading session down -0.28 at 40.99 with 434,976 shares trading hands.